Search

Your search keyword '"Yuen, Hok"' showing total 590 results
Start Over Author "Yuen, Hok"
590 results on '"Yuen, Hok"'

1. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis.

Author

Wannan, Cassandra, Nelson, Barnaby, Addington, Jean, Allott, Kelly, Anticevic, Alan, Arango, Celso, Baker, Justin, McGorry, Patrick, Mittal, Vijay, Nordentoft, Merete, Nunez, Angela, Pasternak, Ofer, Pearlson, Godfrey, Perez, Jesus, Perkins, Diana, Powers, Albert, Roalf, David, Sabb, Fred, Schiffman, Jason, Shah, Jai, Smesny, Stefan, Spark, Jessica, Stone, William, Strauss, Gregory, Tamayo, Zailyn, Torous, John, Upthegrove, Rachel, Vangel, Mark, Verma, Swapna, Wang, Jijun, Rossum, Inge, Wolf, Daniel, Wolff, Phillip, Wood, Stephen, Yung, Alison, Agurto, Carla, Alvarez-Jimenez, Mario, Amminger, Paul, Armando, Marco, Asgari-Targhi, Ameneh, Cahill, John, Carrión, Ricardo, Castro, Eduardo, Cetin-Karayumak, Suheyla, Mallar Chakravarty, M, Cho, Youngsun, Cotter, David, DAlfonso, Simon, Ennis, Michaela, Fadnavis, Shreyas, Fonteneau, Clara, Gao, Caroline, Gupta, Tina, Gur, Raquel, Gur, Ruben, Hamilton, Holly, Hoftman, Gil, Jacobs, Grace, Jarcho, Johanna, Ji, Jie, Kohler, Christian, Lalousis, Paris, Lavoie, Suzie, Lepage, Martin, Liebenthal, Einat, Mervis, Josh, Murty, Vishnu, Nicholas, Spero, Ning, Lipeng, Penzel, Nora, Poldrack, Russell, Polosecki, Pablo, Pratt, Danielle, Rabin, Rachel, Rahimi Eichi, Habiballah, Rathi, Yogesh, Reichenberg, Avraham, Reinen, Jenna, Rogers, Jack, Ruiz-Yu, Bernalyn, Scott, Isabelle, Seitz-Holland, Johanna, Srihari, Vinod, Srivastava, Agrima, Thompson, Andrew, Turetsky, Bruce, Walsh, Barbara, Whitford, Thomas, Wigman, Johanna, Yao, Beier, Yuen, Hok, Ahmed, Uzair, Byun, Andrew, Chung, Yoonho, Do, Kim, Hendricks, Larry, Huynh, Kevin, Jeffries, Clark, Lane, Erlend, and Langholm, Carsten

Subjects
clinical high risk, consortium, early detection, prediction, prevention, psychosis, Humans, Psychotic Disorders, Schizophrenia, Prospective Studies, Adult, Prodromal Symptoms, Young Adult, International Cooperation, Adolescent, Research Design, Male, Female
Abstract

This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the development and use of novel pharmacological interventions for CHR individuals. We present a description of the participating research networks and the data processing analysis and coordination center, their processes for data harmonization across 43 sites from 13 participating countries (recruitment across North America, Australia, Europe, Asia, and South America), data flow and quality assessment processes, data analyses, and the transfer of data to the National Institute of Mental Health (NIMH) Data Archive (NDA) for use by the research community. In an expected sample of approximately 2000 CHR individuals and 640 matched healthy controls, AMP SCZ will collect clinical, environmental, and cognitive data along with multimodal biomarkers, including neuroimaging, electrophysiology, fluid biospecimens, speech and facial expression samples, novel measures derived from digital health technologies including smartphone-based daily surveys, and passive sensing as well as actigraphy. The study will investigate a range of clinical outcomes over a 2-year period, including transition to psychosis, remission or persistence of CHR status, attenuated positive symptoms, persistent negative symptoms, mood and anxiety symptoms, and psychosocial functioning. The global reach of AMP SCZ and its harmonized innovative methods promise to catalyze the development of new treatments to address critical unmet clinical and public health needs in CHR individuals.

Published
2024

2. A Sequential Adaptive Intervention Strategy Targeting Remission and Functional Recovery in Young People at Ultrahigh Risk of Psychosis

Author

McGorry, Patrick D, Mei, Cristina, Amminger, G Paul, Yuen, Hok Pan, Kerr, Melissa, Spark, Jessica, Wallis, Nicky, Polari, Andrea, Baird, Shelley, Buccilli, Kate, Dempsey, Sarah-Jane A, Ferguson, Natalie, Formica, Melanie, Krcmar, Marija, Quinn, Amelia L, Mebrahtu, Yohannes, Ruslins, Arlan, Street, Rebekah, Wannan, Cassandra, Dixon, Lisa, Carter, Cameron, Loewy, Rachel, Niendam, Tara A, Shumway, Martha, and Nelson, Barnaby

Subjects
Biological Psychology, Biomedical and Clinical Sciences, Psychology, Clinical Trials and Supportive Activities, Mental Health, Pediatric, Serious Mental Illness, Clinical Research, Behavioral and Social Science, Pediatric Research Initiative, Brain Disorders, Mental health, Good Health and Well Being, Humans, Female, Adolescent, Psychotic Disorders, Fluoxetine, Quality of Life, Antipsychotic Agents, Recurrence, Treatment Outcome, Other Medical and Health Sciences, Cognitive Sciences, Clinical sciences, Clinical and health psychology
Abstract

ImportanceClinical trials have not established the optimal type, sequence, and duration of interventions for people at ultrahigh risk of psychosis.ObjectiveTo determine the effectiveness of a sequential and adaptive intervention strategy for individuals at ultrahigh risk of psychosis.Design, setting, and participantsThe Staged Treatment in Early Psychosis (STEP) sequential multiple assignment randomized trial took place within the clinical program at Orygen, Melbourne, Australia. Individuals aged 12 to 25 years who were seeking treatment and met criteria for ultrahigh risk of psychosis according to the Comprehensive Assessment of At-Risk Mental States were recruited between April 2016 and January 2019. Of 1343 individuals considered, 342 were recruited.InterventionsStep 1: 6 weeks of support and problem solving (SPS); step 2: 20 weeks of cognitive-behavioral case management (CBCM) vs SPS; and step 3: 26 weeks of CBCM with fluoxetine vs CBCM with placebo with an embedded fast-fail option of ω-3 fatty acids or low-dose antipsychotic medication. Individuals who did not remit progressed through these steps; those who remitted received SPS or monitoring for up to 12 months.Main outcomes and measuresGlobal Functioning: Social and Role scales (primary outcome), Brief Psychiatric Rating Scale, Scale for the Assessment of Negative Symptoms, Montgomery-Åsberg Depression Rating Scale, quality of life, transition to psychosis, and remission and relapse rates.ResultsThe sample comprised 342 participants (198 female; mean [SD] age, 17.7 [3.1] years). Remission rates, reflecting sustained symptomatic and functional improvement, were 8.5%, 10.3%, and 11.4% at steps 1, 2, and 3, respectively. A total of 27.2% met remission criteria at any step. Relapse rates among those who remitted did not significantly differ between SPS and monitoring (step 1: 65.1% vs 58.3%; step 2: 37.7% vs 47.5%). There was no significant difference in functioning, symptoms, and transition rates between SPS and CBCM and between CBCM with fluoxetine and CBCM with placebo. Twelve-month transition rates to psychosis were 13.5% (entire sample), 3.3% (those who ever remitted), and 17.4% (those with no remission).Conclusions and relevanceIn this sequential multiple assignment randomized trial, transition rates to psychosis were moderate, and remission rates were lower than expected, partly reflecting the ambitious criteria set and challenges with real-world treatment fidelity and adherence. While all groups showed mild to moderate functional and symptomatic improvement, this was typically short of remission. While further adaptive trials that address these challenges are needed, findings confirm substantial and sustained morbidity and reveal relatively poor responsiveness to existing treatments.Trial registrationClinicalTrials.gov Identifier: NCT02751632.

Published
2023

3. Baseline data of a sequential multiple assignment randomized trial (STEP study)

Author

Hartmann, Jessica A, Nelson, Barnaby, Amminger, Günther Paul, Spark, Jessica, Yuen, Hok Pan, Kerr, Melissa J, Polari, Andrea, Wallis, Nicky, Blasioli, Julie, Dixon, Lisa, Carter, Cameron, Loewy, Rachel, Niendam, Tara A, Shumway, Martha, and McGorry, Patrick D

Subjects
Prevention, Clinical Trials and Supportive Activities, Brain Disorders, Clinical Research, Mental Health, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Mental health, Adolescent, Antidepressive Agents, Antipsychotic Agents, Diagnostic and Statistical Manual of Mental Disorders, Fatty Acids, Omega-3, Humans, Psychotic Disorders, antidepressant medication, clinical trial, prodrome, psychosis, ultra-high risk, Clinical Sciences, Psychology, Psychiatry
Abstract

AimResearch has shown that preventative intervention in individuals at ultra-high risk of psychosis (UHR) improves symptomatic and functional outcomes. The staged treatment in early psychosis (STEP) trial aims to determine the most effective type, timing and sequence of interventions in the UHR population by sequentially studying the effectiveness of (1) support and problem solving, (2) cognitive-behavioural case management and (3) antidepressant medication with an embedded fast-fail option of (4) omega-3 fatty acids or low-dose antipsychotic medication. This paper presents the recruitment flow and baseline clinical characteristics of the sample.MethodsSTEP is a sequential multiple assignment randomized trial. We present the baseline demographics, clinical characteristics and acceptability and feasibility of this treatment approach as indicated by the flow of participants from first contact up until enrolment into the trial. Recruitment took place between April 2016 and January 2019.ResultsOf 1343, help-seeking young people who were considered for participation, 402 participants were not eligible and 599 declined/disengaged, resulting in a total of 342 participants enrolled in the study. The most common reason for exclusion was an active prescription of antidepressant medication. Eighty-five percent of the enrolled sample had a non-psychotic DSM-5 diagnosis and symptomatic/functional measures showed a moderate level of clinical severity and functional impairment.DiscussionThe present study demonstrates the acceptability and participant's general positive appraisal of sequential treatment. It also shows, in line with other trials in UHR individuals, a significant level of psychiatric morbidity and impairment, demonstrating the clear need for care in this group and that treatment is appropriate.

Published
2022

4. Effects of risperidone/paliperidone versus placebo on cognitive functioning over the first 6 months of treatment for psychotic disorder: secondary analysis of a triple-blind randomised clinical trial

Author

Allott, Kelly, Yuen, Hok Pan, Baldwin, Lara, O’Donoghue, Brian, Fornito, Alex, Chopra, Sidhant, Nelson, Barnaby, Graham, Jessica, Kerr, Melissa J., Proffitt, Tina-Marie, Ratheesh, Aswin, Alvarez-Jimenez, Mario, Harrigan, Susy, Brown, Ellie, Thompson, Andrew D., Pantelis, Christos, Berk, Michael, McGorry, Patrick D., Francey, Shona M., and Wood, Stephen J.

Published
2023
Full Text
View/download PDF

7. Combining Clinical With Cognitive or Magnetic Resonance Imaging Data for Predicting Transition to Psychosis in Ultra High-Risk Patients: Data From the PACE 400 Cohort

Author

Hartmann, Simon, Cearns, Micah, Pantelis, Christos, Dwyer, Dominic, Cavve, Blake, Byrne, Enda, Scott, Isabelle, Yuen, Hok Pan, Gao, Caroline, Allott, Kelly, Lin, Ashleigh, Wood, Stephen J., Wigman, Johanna T.W., Amminger, G. Paul, McGorry, Patrick D., Yung, Alison R., Nelson, Barnaby, and Clark, Scott R.

Published
2024
Full Text
View/download PDF

9. The Addition of Fish Oil to Cognitive Behavioral Case Management for Youth Depression: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial

Author

Amminger, G. Paul, Rice, Simon, Davey, Christopher G., Quinn, Amelia L., Hermens, Daniel F., Zmicerevska, Natalia, Nichles, Alissa, Hickie, Ian, Incerti, Lisa, Weller, Amber, Joseph, Sarah, Hilton, Zarah, Pugh, Charlotte, Rayner, Madeline, Reid, Nate, Ratheesh, Aswin, Yung, Alison R., Yuen, Hok Pan, Mackinnon, Andrew, Hetrick, Sarah, Parker, Alexandra, Street, Rebekah, Berger, Maximus, Berk, Michael, McGorry, Patrick D., and Lin, Ashleigh

Published
2024
Full Text
View/download PDF

10. Brainwide Anatomical Connectivity and Prediction of Longitudinal Outcomes in Antipsychotic-Naïve First-Episode Psychosis

Author

Chopra, Sidhant, Levi, Priscila T., Holmes, Alexander, Orchard, Edwina R., Segal, Ashlea, Francey, Shona M., O’Donoghue, Brian, Cropley, Vanessa L., Nelson, Barnaby, Graham, Jessica, Baldwin, Lara, Yuen, Hok Pan, Allott, Kelly, Alvarez-Jimenez, Mario, Harrigan, Susy, Pantelis, Christos, Wood, Stephen J., McGorry, Patrick, and Fornito, Alex

Published
2024
Full Text
View/download PDF

15. An open label pilot trial of low‐dose lithium for young people at ultra‐high risk for psychosis.

Author

Rice, Simon M., Nelson, Barnaby, Amminger, G. Paul, Francey, Shona M., Phillips, Lisa J., Simmons, Magenta B., Ross, Margaret, Yuen, Hok Pan, Yung, Alison R., O'Gorman, Kieran, McGorry, Patrick D., Wood, Stephen J., and Berger, Gregor E.

Abstract

Aim: Lithium, even at low doses, appears to offer neuroprotection against a wide variety of insults. In this controlled pilot, we examined the safety (i.e., side‐effect profile) of lithium in a sample of young people identified at ultra‐high risk (UHR) for psychosis. The secondary aim was to explore whether lithium provided a signal of clinical efficacy in reducing transition to psychosis compared with treatment as usual (TAU). Methods: Young people attending the PACE clinic at Orygen, Melbourne, were prescribed a fixed dose (450 mg) of lithium (n = 25) or received TAU (n = 78). The primary outcome examined side‐effects, with transition to psychosis, functioning and measures of psychopathology assessed as secondary outcomes. Results: Participants in both groups were functionally compromised (lithium group GAF = 56.6; monitoring group GAF = 56.9). Side‐effect assessment indicated that lithium was well‐tolerated. 64% (n = 16) of participants in the lithium group were lithium‐adherent to week 12. Few cases transitioned to psychosis across the study period; lithium group 4% (n = 1); monitoring group 7.7% (n = 6). There was no difference in time to transition to psychosis between the groups. No group differences were observed in other functioning and symptom domains, although all outcomes improved over time. Conclusions: With a side‐effect profile either comparable to, or better than UHR antipsychotic trials, lithium might be explored for further research with UHR young people. A definitive larger trial is needed to determine the efficacy of lithium in this cohort. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Staged Treatment in Early Psychosis: A sequential multiple assignment randomised trial of interventions for ultra high risk of psychosis patients

Author

Nelson, Barnaby, Amminger, G Paul, Yuen, Hok Pan, Wallis, Nicky, Kerr, Melissa J, Dixon, Lisa, Carter, Cameron, Loewy, Rachel, Niendam, Tara A, Shumway, Martha, Morris, Sarah, Blasioli, Julie, and McGorry, Patrick D

Subjects
Prevention, Mental Health, Clinical Research, Behavioral and Social Science, Patient Safety, Clinical Trials and Supportive Activities, Brain Disorders, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 6.6 Psychological and behavioural, Mental health, Adolescent, Adult, Antidepressive Agents, Child, Cognitive Behavioral Therapy, Combined Modality Therapy, Early Medical Intervention, Humans, Psychotic Disorders, Vulnerable Populations, Young Adult, antidepressant medication, clinical trial, prodrome, psychosis, ultra high risk, Clinical Sciences, Psychology, Psychiatry
Abstract

AimPrevious research indicates that preventive intervention is likely to benefit patients "at risk" of psychosis, in terms of functional improvement, symptom reduction and delay or prevention of onset of threshold psychotic disorder. The primary aim of the current study is to test outcomes of ultra high risk (UHR) patients, primarily functional outcome, in response to a sequential intervention strategy consisting of support and problem solving (SPS), cognitive-behavioural case management and antidepressant medication. A secondary aim is to test biological and psychological variables that moderate and mediate response to this sequential treatment strategy.MethodsThis is a sequential multiple assignment randomised trial (SMART) consisting of three steps: Step 1: SPS (1.5 months); Step 2: SPS vs Cognitive Behavioural Case Management (4.5 months); Step 3: Cognitive Behavioural Case Management + Antidepressant Medication vs Cognitive Behavioural Case Management + Placebo (6 months). The intervention is of 12 months duration in total and participants will be followed up at 18 months and 24 months post baseline.ConclusionThis paper reports on the rationale and protocol of the Staged Treatment in Early Psychosis (STEP) study. With a large sample of 500 UHR participants this study will investigate the most effective type and sequence of treatments for improving functioning and reducing the risk of developing psychotic disorder in this clinical population.

Published
2018

17. Cognitive ability and metabolic physical health in first-episode psychosis

Author

Whitson, Sarah, O'Donoghue, Brian, Hester, Robert, Baldwin, Lara, Harrigan, Susy, Francey, Shona, Graham, Jessica, Nelson, Barnaby, Ratheesh, Aswin, Alvarez-Jimenez, Mario, Fornito, Alex, Pantelis, Christos, Yuen, Hok Pan, Thompson, Andrew, Kerr, Melissa, Berk, Michael, Wood, Stephen J., McGorry, Patrick, and Allott, Kelly

Published
2021
Full Text
View/download PDF

19. Differentiating the effect of antipsychotic medication and illness on brain volume reductions in first-episode psychosis: A Longitudinal, Randomised, Triple-blind, Placebo-controlled MRI Study

Author

Chopra, Sidhant, Fornito, Alex, Francey, Shona M., O’Donoghue, Brian, Cropley, Vanessa, Nelson, Barnaby, Graham, Jessica, Baldwin, Lara, Tahtalian, Steven, Yuen, Hok Pan, Allott, Kelly, Alvarez-Jimenez, Mario, Harrigan, Susy, Sabaroedin, Kristina, Pantelis, Christos, Wood, Stephen J., and McGorry, Patrick

Published
2021
Full Text
View/download PDF

20. The association between migrant status and transition in an ultra-high risk for psychosis population

Author

O’Donoghue, Brian, Geros, Hellen, Sizer, Holly, Addington, Jean, Amminger, G. Paul, Beaden, Carrie E., Cadenhead, Kristin S., Cannon, Tyrone D., Cornblatt, Barbara A., Berger, Gregor Emanuel, Chen, Eric Y. H., de Haan, Lieuwe, Hartmann, Jessica A., Hickie, Ian B., Ising, Helga K., Lavoie, Suzie, Lin, Ashleigh, Markulev, Connie, Mathalon, Daniel H., McGlashan, Thomas H., Mifsud, Nathan G., Mossaheb, Nilufar, Nieman, Dorien H., Nordentoft, Merete, Perkins, Diana O., Riecher-Rössler, Anita, Schäfer, Miriam R., Schlögelhofer, Monika, Seidman, Larry J., Smesny, Stephan, Thompson, Andrew, Tsuang, Ming T., van der Gaag, Mark, Verma, Swapna, Walker, Elaine F., Wood, Stephen J., Woods, Scott W., Yuen, Hok Pan, Yung, Alison Ruth, McGorry, Patrick D., and Nelson, Barnaby

Published
2021
Full Text
View/download PDF

21. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ):Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

Author

Wannan, Cassandra M.J., Nelson, Barnaby, Addington, Jean, Allott, Kelly, Anticevic, Alan, Arango, Celso, Baker, Justin T., Bearden, Carrie E., Billah, Tashrif, Bouix, Sylvain, Broome, Matthew R., Buccilli, Kate, Cadenhead, Kristin S., Calkins, Monica E., Cannon, Tyrone D., Cecci, Guillermo, Chen, Eric Yu Hai, Cho, Kang Ik K., Choi, Jimmy, Clark, Scott R., Coleman, Michael J., Conus, Philippe, Corcoran, Cheryl M., Cornblatt, Barbara A., Diaz-Caneja, Covadonga M., Dwyer, Dominic, Ebdrup, Bjørn H., Ellman, Lauren M., Fusar-Poli, Paolo, Galindo, Liliana, Gaspar, Pablo A., Gerber, Carla, Glenthøj, Louise Birkedal, Glynn, Robert, Harms, Michael P., Horton, Leslie E., Kahn, René S., Kambeitz, Joseph, Kambeitz-Ilankovic, Lana, Kane, John M., Kapur, Tina, Keshavan, Matcheri S., Kim, Sung Wan, Koutsouleris, Nikolaos, Kubicki, Marek, Kwon, Jun Soo, Langbein, Kerstin, Lewandowski, Kathryn E., Light, Gregory A., Mamah, Daniel, Marcy, Patricia J., Mathalon, Daniel H., McGorry, Patrick D., Mittal, Vijay A., Nordentoft, Merete, Nunez, Angela, Pasternak, Ofer, Pearlson, Godfrey D., Perez, Jesus, Perkins, Diana O., Powers, Albert R., Roalf, David R., Sabb, Fred W., Schiffman, Jason, Shah, Jai L., Smesny, Stefan, Spark, Jessica, Stone, William S., Strauss, Gregory P., Tamayo, Zailyn, Torous, John, Upthegrove, Rachel, Vangel, Mark, Verma, Swapna, Wang, Jijun, Rossum, Inge Winter van, Wolf, Daniel H., Wolff, Phillip, Wood, Stephen J., Yung, Alison R., Agurto, Carla, Alvarez-Jimenez, Mario, Amminger, Paul, Armando, Marco, Asgari-Targhi, Ameneh, Cahill, John, Carrión, Ricardo E., Castro, Eduardo, Cetin-Karayumak, Suheyla, Mallar Chakravarty, M., Cho, Youngsun T., Cotter, David, D'Alfonso, Simon, Ennis, Michaela, Fadnavis, Shreyas, Fonteneau, Clara, Gao, Caroline, Gupta, Tina, Gur, Raquel E., Gur, Ruben C., Hamilton, Holly K., Hoftman, Gil D., Jacobs, Grace R., Jarcho, Johanna, Ji, Jie Lisa, Kohler, Christian G., Lalousis, Paris Alexandros, Lavoie, Suzie, Lepage, Martin, Liebenthal, Einat, Mervis, Josh, Murty, Vishnu, Nicholas, Spero C., Ning, Lipeng, Penzel, Nora, Poldrack, Russell, Polosecki, Pablo, Pratt, Danielle N., Rabin, Rachel, Rahimi Eichi, Habiballah, Rathi, Yogesh, Reichenberg, Avraham, Reinen, Jenna, Rogers, Jack, Ruiz-Yu, Bernalyn, Scott, Isabelle, Seitz-Holland, Johanna, Srihari, Vinod H., Srivastava, Agrima, Thompson, Andrew, Turetsky, Bruce I., Walsh, Barbara C., Whitford, Thomas, Wigman, Johanna T.W., Yao, Beier, Yuen, Hok Pan, Ahmed, Uzair, Byun, Andrew Jin Soo, Chung, Yoonho, Do, Kim, Hendricks, Larry, Huynh, Kevin, Jeffries, Clark, Lane, Erlend, Langholm, Carsten, Lin, Eric, Mantua, Valentina, Santorelli, Gennarina, Ruparel, Kosha, Zoupou, Eirini, Adasme, Tatiana, Addamo, Lauren, Adery, Laura, Ali, Munaza, Auther, Andrea, Aversa, Samantha, Baek, Seon Hwa, Bates, Kelly, Bathery, Alyssa, Bayer, Johanna M.M., Beedham, Rebecca, Bilgrami, Zarina, Birch, Sonia, Bonoldi, Ilaria, Borders, Owen, Borgatti, Renato, Brown, Lisa, Bruna, Alejandro, Carrington, Holly, Castillo-Passi, Rolando I., Chen, Justine, Cheng, Nicholas, Ching, Ann Ee, Clifford, Chloe, Colton, Beau Luke, Contreras, Pamela, Corral, Sebastián, Damiani, Stefano, Done, Monica, Estradé, Andrés, Etuka, Brandon Asika, Formica, Melanie, Furlan, Rachel, Geljic, Mia, Germano, Carmela, Getachew, Ruth, Goncalves, Mathias, Haidar, Anastasia, Hartmann, Jessica, Jo, Anna, John, Omar, Kerins, Sarah, Kerr, Melissa, Kesselring, Irena, Kim, Honey, Kim, Nicholas, Kinney, Kyle, Krcmar, Marija, Kotler, Elana, Lafanechere, Melanie, Lee, Clarice, Llerena, Joshua, Markiewicz, Christopher, Matnejl, Priya, Maturana, Alejandro, Mavambu, Aissata, Mayol-Troncoso, Rocío, McDonnell, Amelia, McGowan, Alessia, McLaughlin, Danielle, McIlhenny, Rebecca, McQueen, Brittany, Mebrahtu, Yohannes, Mensi, Martina, Hui, Christy Lai Ming, Suen, Yi Nam, Wong, Stephanie Ming Yin, Morrell, Neal, Omar, Mariam, Partridge, Alice, Phassouliotis, Christina, Pichiecchio, Anna, Politi, Pierluigi, Porter, Christian, Provenzani, Umberto, Prunier, Nicholas, Raj, Jasmine, Ray, Susan, Rayner, Victoria, Reyes, Manuel, Reynolds, Kate, Rush, Sage, Salinas, Cesar, Shetty, Jashmina, Snowball, Callum, Tod, Sophie, Turra-Fariña, Gabriel, Valle, Daniela, Veale, Simone, Whitson, Sarah, Wickham, Alana, Youn, Sarah, Zamorano, Francisco, Zavaglia, Elissa, Zinberg, Jamie, Woods, Scott W., Shenton, Martha E., Wannan, Cassandra M.J., Nelson, Barnaby, Addington, Jean, Allott, Kelly, Anticevic, Alan, Arango, Celso, Baker, Justin T., Bearden, Carrie E., Billah, Tashrif, Bouix, Sylvain, Broome, Matthew R., Buccilli, Kate, Cadenhead, Kristin S., Calkins, Monica E., Cannon, Tyrone D., Cecci, Guillermo, Chen, Eric Yu Hai, Cho, Kang Ik K., Choi, Jimmy, Clark, Scott R., Coleman, Michael J., Conus, Philippe, Corcoran, Cheryl M., Cornblatt, Barbara A., Diaz-Caneja, Covadonga M., Dwyer, Dominic, Ebdrup, Bjørn H., Ellman, Lauren M., Fusar-Poli, Paolo, Galindo, Liliana, Gaspar, Pablo A., Gerber, Carla, Glenthøj, Louise Birkedal, Glynn, Robert, Harms, Michael P., Horton, Leslie E., Kahn, René S., Kambeitz, Joseph, Kambeitz-Ilankovic, Lana, Kane, John M., Kapur, Tina, Keshavan, Matcheri S., Kim, Sung Wan, Koutsouleris, Nikolaos, Kubicki, Marek, Kwon, Jun Soo, Langbein, Kerstin, Lewandowski, Kathryn E., Light, Gregory A., Mamah, Daniel, Marcy, Patricia J., Mathalon, Daniel H., McGorry, Patrick D., Mittal, Vijay A., Nordentoft, Merete, Nunez, Angela, Pasternak, Ofer, Pearlson, Godfrey D., Perez, Jesus, Perkins, Diana O., Powers, Albert R., Roalf, David R., Sabb, Fred W., Schiffman, Jason, Shah, Jai L., Smesny, Stefan, Spark, Jessica, Stone, William S., Strauss, Gregory P., Tamayo, Zailyn, Torous, John, Upthegrove, Rachel, Vangel, Mark, Verma, Swapna, Wang, Jijun, Rossum, Inge Winter van, Wolf, Daniel H., Wolff, Phillip, Wood, Stephen J., Yung, Alison R., Agurto, Carla, Alvarez-Jimenez, Mario, Amminger, Paul, Armando, Marco, Asgari-Targhi, Ameneh, Cahill, John, Carrión, Ricardo E., Castro, Eduardo, Cetin-Karayumak, Suheyla, Mallar Chakravarty, M., Cho, Youngsun T., Cotter, David, D'Alfonso, Simon, Ennis, Michaela, Fadnavis, Shreyas, Fonteneau, Clara, Gao, Caroline, Gupta, Tina, Gur, Raquel E., Gur, Ruben C., Hamilton, Holly K., Hoftman, Gil D., Jacobs, Grace R., Jarcho, Johanna, Ji, Jie Lisa, Kohler, Christian G., Lalousis, Paris Alexandros, Lavoie, Suzie, Lepage, Martin, Liebenthal, Einat, Mervis, Josh, Murty, Vishnu, Nicholas, Spero C., Ning, Lipeng, Penzel, Nora, Poldrack, Russell, Polosecki, Pablo, Pratt, Danielle N., Rabin, Rachel, Rahimi Eichi, Habiballah, Rathi, Yogesh, Reichenberg, Avraham, Reinen, Jenna, Rogers, Jack, Ruiz-Yu, Bernalyn, Scott, Isabelle, Seitz-Holland, Johanna, Srihari, Vinod H., Srivastava, Agrima, Thompson, Andrew, Turetsky, Bruce I., Walsh, Barbara C., Whitford, Thomas, Wigman, Johanna T.W., Yao, Beier, Yuen, Hok Pan, Ahmed, Uzair, Byun, Andrew Jin Soo, Chung, Yoonho, Do, Kim, Hendricks, Larry, Huynh, Kevin, Jeffries, Clark, Lane, Erlend, Langholm, Carsten, Lin, Eric, Mantua, Valentina, Santorelli, Gennarina, Ruparel, Kosha, Zoupou, Eirini, Adasme, Tatiana, Addamo, Lauren, Adery, Laura, Ali, Munaza, Auther, Andrea, Aversa, Samantha, Baek, Seon Hwa, Bates, Kelly, Bathery, Alyssa, Bayer, Johanna M.M., Beedham, Rebecca, Bilgrami, Zarina, Birch, Sonia, Bonoldi, Ilaria, Borders, Owen, Borgatti, Renato, Brown, Lisa, Bruna, Alejandro, Carrington, Holly, Castillo-Passi, Rolando I., Chen, Justine, Cheng, Nicholas, Ching, Ann Ee, Clifford, Chloe, Colton, Beau Luke, Contreras, Pamela, Corral, Sebastián, Damiani, Stefano, Done, Monica, Estradé, Andrés, Etuka, Brandon Asika, Formica, Melanie, Furlan, Rachel, Geljic, Mia, Germano, Carmela, Getachew, Ruth, Goncalves, Mathias, Haidar, Anastasia, Hartmann, Jessica, Jo, Anna, John, Omar, Kerins, Sarah, Kerr, Melissa, Kesselring, Irena, Kim, Honey, Kim, Nicholas, Kinney, Kyle, Krcmar, Marija, Kotler, Elana, Lafanechere, Melanie, Lee, Clarice, Llerena, Joshua, Markiewicz, Christopher, Matnejl, Priya, Maturana, Alejandro, Mavambu, Aissata, Mayol-Troncoso, Rocío, McDonnell, Amelia, McGowan, Alessia, McLaughlin, Danielle, McIlhenny, Rebecca, McQueen, Brittany, Mebrahtu, Yohannes, Mensi, Martina, Hui, Christy Lai Ming, Suen, Yi Nam, Wong, Stephanie Ming Yin, Morrell, Neal, Omar, Mariam, Partridge, Alice, Phassouliotis, Christina, Pichiecchio, Anna, Politi, Pierluigi, Porter, Christian, Provenzani, Umberto, Prunier, Nicholas, Raj, Jasmine, Ray, Susan, Rayner, Victoria, Reyes, Manuel, Reynolds, Kate, Rush, Sage, Salinas, Cesar, Shetty, Jashmina, Snowball, Callum, Tod, Sophie, Turra-Fariña, Gabriel, Valle, Daniela, Veale, Simone, Whitson, Sarah, Wickham, Alana, Youn, Sarah, Zamorano, Francisco, Zavaglia, Elissa, Zinberg, Jamie, Woods, Scott W., and Shenton, Martha E.

Abstract

This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the development and use of novel pharmacological interventions for CHR individuals. We present a description of the participating research networks and the data processing analysis and coordination center, their processes for data harmonization across 43 sites from 13 participating countries (recruitment across North America, Australia, Europe, Asia, and South America), data flow and quality assessment processes, data analyses, and the transfer of data to the National Institute of Mental Health (NIMH) Data Archive (NDA) for use by the research community. In an expected sample of approximately 2000 CHR individuals and 640 matched healthy controls, AMP SCZ will collect clinical, environmental, and cognitive data along with multimodal biomarkers, including neuroimaging, electrophysiology, fluid biospecimens, speech and facial expression samples, novel measures derived from digital health technologies including smartphone-based daily surveys, and passive sensing as well as actigraphy. The study will investigate a range of clinical outcomes over a 2-year period, including transition to psychosis, remission or persistence of CHR status, attenuated positive symptoms, persistent negative symptoms, mood and anxiety symptoms, and psychosocial functioning. The global reach of AMP SCZ and its harmonized innovative methods promise to catalyze the development of new treatments to address critical unmet clinical and public health needs in CHR individuals., This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the development and use of novel pharmacological interventions for CHR individuals. We present a description of the participating research networks and the data processing analysis and coordination center, their processes for data harmonization across 43 sites from 13 participating countries (recruitment across North America, Australia, Europe, Asia, and South America), data flow and quality assessment processes, data analyses, and the transfer of data to the National Institute of Mental Health (NIMH) Data Archive (NDA) for use by the research community. In an expected sample of approximately 2000 CHR individuals and 640 matched healthy controls, AMP SCZ will collect clinical, environmental, and cognitive data along with multimodal biomarkers, including neuroimaging, electrophysiology, fluid biospecimens, speech and facial expression samples, novel measures derived from digital health technologies including smartphone-based daily surveys, and passive sensing as well as actigraphy. The study will investigate a range of clinical outcomes over a 2-year period, including transition to psychosis, remission or persistence of CHR status, attenuated positive symptoms, persistent negative symptoms, mood and anxiety symptoms, and psychosocial functioning. The global reach of AMP SCZ and its harmonized innovative methods promise to catalyze the development of new treatments to address critical unmet clinical and public health needs in CHR individuals.

Published
2024

22. The self, neuroscience and psychosis study:Testing a neurophenomenological model of the onset of psychosis

Author

Krcmar, Marija, Wannan, Cassandra M.J., Lavoie, Suzie, Allott, Kelly, Davey, Christopher G., Yuen, Hok Pan, Whitford, Thomas, Formica, Melanie, Youn, Sarah, Shetty, Jashmina, Beedham, Rebecca, Rayner, Victoria, Murray, Graham, Polari, Andrea, Gawęda, Łukasz, Koren, Dan, Sass, Louis, Parnas, Josef, Rasmussen, Andreas R., McGorry, Patrick, Hartmann, Jessica A., Nelson, Barnaby, Krcmar, Marija, Wannan, Cassandra M.J., Lavoie, Suzie, Allott, Kelly, Davey, Christopher G., Yuen, Hok Pan, Whitford, Thomas, Formica, Melanie, Youn, Sarah, Shetty, Jashmina, Beedham, Rebecca, Rayner, Victoria, Murray, Graham, Polari, Andrea, Gawęda, Łukasz, Koren, Dan, Sass, Louis, Parnas, Josef, Rasmussen, Andreas R., McGorry, Patrick, Hartmann, Jessica A., and Nelson, Barnaby

Abstract

Aim Basic self disturbance is a putative core vulnerability marker of schizophrenia spectrum disorders. The primary aims of the Self, Neuroscience and Psychosis (SNAP) study are to: (1) empirically test a previously described neurophenomenological self-disturbance model of psychosis by examining the relationship between specific clinical, neurocognitive, and neurophysiological variables in UHR patients, and (2) develop a prediction model using these neurophenomenological disturbances for persistence or deterioration of UHR symptoms at 12-month follow-up. Methods SNAP is a longitudinal observational study. Participants include 400 UHR individuals, 100 clinical controls with no attenuated psychotic symptoms, and 50 healthy controls. All participants complete baseline clinical and neurocognitive assessments and electroencephalography. The UHR sample are followed up for a total of 24 months, with clinical assessment completed every 6 months. Results This paper presents the protocol of the SNAP study, including background rationale, aims and hypotheses, design, and assessment procedures. Conclusions The SNAP study will test whether neurophenomenological disturbances associated with basic self-disturbance predict persistence or intensification of UHR symptomatology over a 2-year follow up period, and how specific these disturbances are to a clinical population with attenuated psychotic symptoms. This may ultimately inform clinical care and pathoaetiological models of psychosis., Aim: Basic self disturbance is a putative core vulnerability marker of schizophrenia spectrum disorders. The primary aims of the Self, Neuroscience and Psychosis (SNAP) study are to: (1) empirically test a previously described neurophenomenological self-disturbance model of psychosis by examining the relationship between specific clinical, neurocognitive, and neurophysiological variables in UHR patients, and (2) develop a prediction model using these neurophenomenological disturbances for persistence or deterioration of UHR symptoms at 12-month follow-up. Methods: SNAP is a longitudinal observational study. Participants include 400 UHR individuals, 100 clinical controls with no attenuated psychotic symptoms, and 50 healthy controls. All participants complete baseline clinical and neurocognitive assessments and electroencephalography. The UHR sample are followed up for a total of 24 months, with clinical assessment completed every 6 months. Results: This paper presents the protocol of the SNAP study, including background rationale, aims and hypotheses, design, and assessment procedures. Conclusions: The SNAP study will test whether neurophenomenological disturbances associated with basic self-disturbance predict persistence or intensification of UHR symptomatology over a 2-year follow up period, and how specific these disturbances are to a clinical population with attenuated psychotic symptoms. This may ultimately inform clinical care and pathoaetiological models of psychosis.

Published
2024

23. Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis

Author

Alqarni, Ayedh, Mitchell, Todd W., McGorry, Patrick D., Nelson, Barnaby, Markulev, Connie, Yuen, Hok Pan, Schäfer, Miriam R., Berger, Maximus, Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stephan, Hickie, Ian B., Berger, Gregor E., Chen, Eric Y.H., de Haan, Lieuwe, Nieman, Dorien H., Nordentoft, Merete, Riecher-Rössler, Anita, Verma, Swapna, Thompson, Andrew, Yung, Alison Ruth, Meyer, Barbara J., and Amminger, G. Paul

Published
2020
Full Text
View/download PDF

24. Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people

Author

Alqarni, Ayedh, Mitchell, Todd W., McGorry, Patrick D., Nelson, Barnaby, Markulev, Connie, Yuen, Hok Pan, Schäfer, Miriam R., Berger, Maximus, Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stefan, Hickie, Ian B., Berger, Gregor E., Chen, Eric Y.H., de Haan, Lieuwe, Nieman, Dorien H., Nordentoft, Merete, Riecher-Rössler, Anita, Verma, Swapna, Thompson, Andrew, Yung, Alison Ruth, Amminger, G. Paul, and Meyer, Barbara J.

Published
2020
Full Text
View/download PDF

26. Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial

Author

Mallawaarachchi, Sumudu Rasangi, Amminger, G. Paul, Farhall, John, Bolt, Luke K., Nelson, Barnaby, Yuen, Hok Pan, McGorry, Patrick D., Markulev, Connie, Schäfer, Miriam R., Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stefan, Hickie, Ian B., Berger, Gregor Emanuel, Chen, Eric Y.H., de Haan, Lieuwe, Nieman, Dorien H., Nordentoft, Merete, Riecher-Rössler, Anita, Verma, Swapna, Thompson, Andrew, Yung, Alison Ruth, and Allott, Kelly A.

Published
2020
Full Text
View/download PDF

28. The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis

Author

Amminger, G. Paul, Nelson, Barnaby, Markulev, Connie, Yuen, Hok Pan, Schäfer, Miriam R., Berger, Maximus, Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stephan, Hickie, Ian B., Berger, Gregor E., Chen, Eric Y.H., de Haan, Lieuwe, Nieman, Dorien H., Nordentoft, Merete, Riecher-Rössler, Anita, Verma, Swapna, Thompson, Andrew, Yung, Alison Ruth, and McGorry, Patrick D.

Published
2020
Full Text
View/download PDF

29. Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial

Author

Hartmann, Jessica A., Schmidt, Stefanie J., McGorry, Patrick D., Berger, Maximus, Berger, Gregor E., Chen, Eric Y.H., de Haan, Lieuwe, Hickie, Ian B., Lavoie, Suzie, Markulev, Connie, Mossaheb, Nilufar, Nieman, Dorien H., Nordentoft, Merete, Polari, Andrea, Riecher-Rössler, Anita, Schäfer, Miriam R., Schlögelhofer, Monika, Smesny, Stefan, Thompson, Andrew, Verma, Swapna K., Yuen, Hok Pan, Yung, Alison R., Amminger, G. Paul, and Nelson, Barnaby

Published
2020
Full Text
View/download PDF

30. Brain-wide Disruptions of Anatomical Connectivity in Antipsychotic-Naive First Episode Psychosis

Author

Chopra, Sidhant, primary, Levi, Priscila T, additional, Holmes, Alexander, additional, Orchard, Edwina R, additional, Segal, Ashlea, additional, Francey, Shona M, additional, ODonoghue, Brian, additional, Cropley, Vanessa, additional, Nelson, Barnaby, additional, Graham, Jessica, additional, Baldwin, Lara, additional, Yuen, Hok Pan, additional, Allott, Kelly, additional, Alvarez-Jimenez, Mario, additional, Harrigan, Susy, additional, Pantelis, Christos, additional, Wood, Stephen J, additional, McGorry, Patrick, additional, and Fornito, Alex, additional

Published
2023
Full Text
View/download PDF

33. Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial

Author

Bolt, Luke K., Amminger, G. Paul, Farhall, John, McGorry, Patrick D., Nelson, Barnaby, Markulev, Connie, Yuen, Hok Pan, Schäfer, Miriam R., Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stefan, Hickie, Ian B., Berger, Gregor Emanuel, Chen, Eric Y.H., de Haan, Lieuwe, Nieman, Dorien H., Nordentoft, Merete, Riecher-Rössler, Anita, Verma, Swapna, Thompson, Andrew, Yung, Alison Ruth, and Allott, Kelly A.

Published
2019
Full Text
View/download PDF

34. The self, neuroscience and psychosis study: Testing a neurophenomenological model of the onset of psychosis.

Author

Krcmar, Marija, Wannan, Cassandra M. J., Lavoie, Suzie, Allott, Kelly, Davey, Christopher G., Yuen, Hok Pan, Whitford, Thomas, Formica, Melanie, Youn, Sarah, Shetty, Jashmina, Beedham, Rebecca, Rayner, Victoria, Murray, Graham, Polari, Andrea, Gawęda, Łukasz, Koren, Dan, Sass, Louis, Parnas, Josef, Rasmussen, Andreas R., and McGorry, Patrick

Subjects
PSYCHOSES, SELF, NEUROSCIENCES
Abstract

Aim: Basic self disturbance is a putative core vulnerability marker of schizophrenia spectrum disorders. The primary aims of the Self, Neuroscience and Psychosis (SNAP) study are to: (1) empirically test a previously described neurophenomenological self‐disturbance model of psychosis by examining the relationship between specific clinical, neurocognitive, and neurophysiological variables in UHR patients, and (2) develop a prediction model using these neurophenomenological disturbances for persistence or deterioration of UHR symptoms at 12‐month follow‐up. Methods: SNAP is a longitudinal observational study. Participants include 400 UHR individuals, 100 clinical controls with no attenuated psychotic symptoms, and 50 healthy controls. All participants complete baseline clinical and neurocognitive assessments and electroencephalography. The UHR sample are followed up for a total of 24 months, with clinical assessment completed every 6 months. Results: This paper presents the protocol of the SNAP study, including background rationale, aims and hypotheses, design, and assessment procedures. Conclusions: The SNAP study will test whether neurophenomenological disturbances associated with basic self‐disturbance predict persistence or intensification of UHR symptomatology over a 2‐year follow up period, and how specific these disturbances are to a clinical population with attenuated psychotic symptoms. This may ultimately inform clinical care and pathoaetiological models of psychosis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Network-Based Spreading of Gray Matter Changes Across Different Stages of Psychosis

Author

Chopra, Sidhant, primary, Segal, Ashlea, additional, Oldham, Stuart, additional, Holmes, Alexander, additional, Sabaroedin, Kristina, additional, Orchard, Edwina R., additional, Francey, Shona M., additional, O’Donoghue, Brian, additional, Cropley, Vanessa, additional, Nelson, Barnaby, additional, Graham, Jessica, additional, Baldwin, Lara, additional, Tiego, Jeggan, additional, Yuen, Hok Pan, additional, Allott, Kelly, additional, Alvarez-Jimenez, Mario, additional, Harrigan, Susy, additional, Fulcher, Ben D., additional, Aquino, Kevin, additional, Pantelis, Christos, additional, Wood, Stephen J., additional, Bellgrove, Mark, additional, McGorry, Patrick D., additional, and Fornito, Alex, additional

Published
2023
Full Text
View/download PDF

36. Clinical trajectories in the ultra-high risk for psychosis population

Author

Polari, Andrea, Lavoie, Suzie, Yuen, Hok-Pan, Amminger, Paul, Berger, Gregor, Chen, Eric, deHaan, Lieuwe, Hartmann, Jessica, Markulev, Connie, Melville, Fritha, Nieman, Dorien, Nordentoft, Merete, Riecher-Rössler, Anita, Smesny, Stefan, Stratford, John, Verma, Swapna, Yung, Alison, McGorry, Patrick, and Nelson, Barnaby

Published
2018
Full Text
View/download PDF

40. Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis

Author

Hartmann, Jessica A., McGorry, Patrick D., Schmidt, Stefanie J., Amminger, G. Paul, Yuen, Hok Pan, Markulev, Connie, Berger, Gregor E., Chen, Eric Y.H., de Haan, Lieuwe, Hickie, Ian B., Lavoie, Suzie, McHugh, Meredith J., Mossaheb, Nilufar, Nieman, Dorien H., Nordentoft, Merete, Riecher-Rössler, Anita, Schäfer, Miriam R., Schlögelhofer, Monika, Smesny, Stefan, Thompson, Andrew, Verma, Swapna Kamal, Yung, Alison R., and Nelson, Barnaby

Published
2017

41. The self, neuroscience and psychosis study: Testing a neurophenomenological model of the onset of psychosis

Author

Krcmar, Marija, primary, Wannan, Cassandra M. J., additional, Lavoie, Suzie, additional, Allott, Kelly, additional, Davey, Christopher G., additional, Yuen, Hok Pan, additional, Whitford, Thomas, additional, Formica, Melanie, additional, Youn, Sarah, additional, Shetty, Jashmina, additional, Beedham, Rebecca, additional, Rayner, Victoria, additional, Murray, Graham, additional, Polari, Andrea, additional, Gawęda, Łukasz, additional, Koren, Dan, additional, Sass, Louis, additional, Parnas, Josef, additional, Rasmussen, Andreas R., additional, McGorry, Patrick, additional, Hartmann, Jessica A., additional, and Nelson, Barnaby, additional

Published
2023
Full Text
View/download PDF

42. 47. The Structural Connectome Shapes Grey Matter Changes Across the Psychosis Continuum

Author

Chopra, Sidhant, primary, Oldham, Stuart, additional, Segal, Ashlea, additional, Holmes, Alex, additional, Sabaroedin, Kristina, additional, Orchard, Edwina, additional, Francey, Shona, additional, O'Donoghue, Brian, additional, Cropley, Vanessa, additional, Nelson, Barnaby, additional, Graham, Jessica, additional, Baldwin, Lara, additional, Tiego, Jeggan, additional, Yuen, Hok Pan, additional, Allott, Kelly, additional, Alvarez-Jimenez, Mario, additional, Harrigan, Susy, additional, Fulcher, Ben, additional, Aquino, Kevin, additional, Pantelis, Christos, additional, Wood, Stephen J., additional, Bellgrove, Mark, additional, McGorry, Patrick, additional, and Fornito, Alex, additional

Published
2023
Full Text
View/download PDF

47. The Addition of Fish Oil to Cognitive Behavioural Case Management for Youth Depression (YoDA-F): A Randomised, Double-Blind, Placebo-Controlled, Multicentre Clinical Trial

Author

Amminger, G Paul, Rice, Simon, Davey, Christopher G, Quinn, Amelia L, Hermens, Daniel F, Zmicerevska, Natalia, Nichles, Alissa, Hickie, Ian, Incerti, Lisa, Weller, Amber, Joseph, Sarah, Hilton, Zarah, Pugh, Charlotte, Rayner, Madeline, Reid, Nate, Ratheesh, Aswin, Yung, Alison R, Yuen, Hok Pan, Mackinnon, Andrew, Hetrick, Sarah, Parker, Alexandra, Street, Rebekah, Berger, Maximus, Berk, Michael, McGorry, Patrick D, and Lin, Ashleigh

Subjects
610 Medicine & health
Abstract

BACKGROUND Clinical trials suggest long-chain omega-3 polyunsaturated fatty acids (n-3 PUFA; 'fish oil') may reduce depressive symptoms in adults with MDD. Hence, n-3 PUFA may be a potential treatment for depression in youth. METHODS Participants were aged 15-25 years with MDD who sought care in one of three government-funded mental health services for young people in metropolitan Melbourne, Perth, or Sydney, Australia. Participants were randomly assigned in a double-blind, parallel-arm design to receive 'fish oil' (840 mg of eicosapentaenoic acid and 560 mg of docosahexaenoic acid) or placebo capsules as adjunct to cognitive behavioural case management (CBCM). All participants were offered fortnightly 50-minute CBCM sessions delivered by qualified therapists (treatment as usual) at the study sites during the intervention period. The primary outcome was change in the interviewer-rated Quick Inventory of Depressive Symptomatology, Adolescent Version (QIDS-A17-C) score at 12 weeks. Erythrocyte n-3 PUFA levels were assessed pre-post intervention. RESULTS 233 young people were randomised to the treatment arms: 115 participants to the n-3 PUFA and 118 to the placebo group. Mean change from baseline in the QIDS-A17-C score was -5.8 in the n-3 PUFA group and -5.6 in the placebo group (mean difference, 0.2; 95% CI -1.1 to 1.5; p=0.75). Erythrocyte PUFA levels were not associated with depression severity at any timepoint. The incidence and severity of adverse events were similar in the two groups. CONCLUSIONS This placebo-controlled trial and biomarker analysis found no evidence to support the use of fish oil for treatment in young people with MDD.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results